Rosuvastatin + placebo + aspirin + placebo

ApprovedCompleted

1 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Atherosclerosis

Conditions

Atherosclerosis, Thromboembolism, Systemic Lupus Erythematosus

Trial Timeline

Jun 1, 2006 → Dec 1, 2009

NCT ID

NCT00371501

About Rosuvastatin + placebo + aspirin + placebo

Rosuvastatin + placebo + aspirin + placebo is a approved stage product being developed by AstraZeneca for Atherosclerosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00371501. Target conditions include Atherosclerosis, Thromboembolism, Systemic Lupus Erythematosus.

What happened to similar drugs?

8 of 20 similar drugs in Atherosclerosis were approved

Approved (8) Terminated (4) Active (10)

🔄Orforglipron + PlaceboEli LillyPhase 3

🔄Olmesartan medoxomil + PlaceboDaiichi SankyoPhase 3

🔄Bempedoic acid + Ezetimibe + Rosuvastatin + AtorvastatinDaiichi SankyoPhase 3

✅Rosuvastatin + PlaceboAstraZenecaApproved

🔄Rosuvastatin + AtorvastatinAstraZenecaPhase 3

🔄Rosuvastatin + PlaceboAstraZenecaPhase 3

✅Rosuvastatin (5mg，10mg，20mg) + Rosuvastatin 5mgAstraZenecaApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00371501	Approved	Completed	Jun 1, 2006	Dec 1, 2009	Atherosclerosis

Competing Products

20 competing products in Atherosclerosis

See all competitors

Product	Company	Stage	Hype Score
Orforglipron + Placebo	Eli Lilly	Phase 3	47
Olmesartan medoxomil + Placebo	Daiichi Sankyo	Phase 3	40
Pactimibe sulfate	Daiichi Sankyo	Phase 2/3	30
Pactimibe	Daiichi Sankyo	Phase 2	35
Bempedoic acid + Ezetimibe + Rosuvastatin + Atorvastatin	Daiichi Sankyo	Phase 3	47
Micronized 17B-estradiol	Johnson & Johnson	Phase 2/3	38
Rosuvastatin + Placebo	AstraZeneca	Approved	35
rosuvastatin + placebo	AstraZeneca	Phase 1	29
Rosuvastatin + Placebo	AstraZeneca	Phase 1	29
Rosuvastatin + Atorvastatin	AstraZeneca	Phase 3	40
Rosuvastatin + Placebo	AstraZeneca	Phase 3	40
Rosuvastatin (5mg，10mg，20mg) + Rosuvastatin 5mg	AstraZeneca	Approved	39
Vorapaxar + Placebo	Merck	Phase 3	40
Vorapaxar + Placebo + Aspirin + Clopidogrel	Merck	Phase 2	35
Niacin/simvastatin compared to simvastatin alone at 2 doses	Merck	Approved	43
lovastatin	Merck	Phase 2/3	38
Ezetimibe + Placebo	Merck	Approved	43
Vorapaxar + Placebo	Merck	Phase 3	32
Niaspan	Merck	Pre-clinical	22
MK0633	Merck	Phase 2	35